| Sep'19 | Sep'18 | Sep'17 | Sep'16 | Sep'15 | Sep'14 | Sep'13 | Sep'12 | Sep'11 |
|---|---|---|---|---|---|---|---|---|
Royalty revenue | ||||||||
205,197 | 206,625 | 102,814 | 88,268 | 160,880 | 47,741 | 32,053 | 41,706 | 41,882 |
Operating expenses: | ||||||||
Research and development | ||||||||
142,213 | 94,856 | 57,451 | 40,461 | 23,189 | 18,740 | 16,841 | 15,115 | 11,547 |
General and administrative | ||||||||
26,246 | 23,441 | 20,749 | 16,966 | 13,543 | 10,016 | 6,183 | 5,302 | 5,036 |
Total operating expenses | ||||||||
168,459 | 118,297 | 78,200 | 57,427 | 36,732 | 28,756 | 23,024 | 20,417 | 16,583 |
Income (loss) from operations | ||||||||
36,738 | 88,328 | 24,614 | 30,841 | 124,148 | 18,985 | 9,029 | 21,289 | 25,299 |
Other income (expense): | ||||||||
Interest income (expense), net | ||||||||
8,819 | 4,852 | 2,492 | 1,690 | - | - | - | - | - |
Therapeutic tax credit | ||||||||
- | - | - | - | - | - | - | - | -750 |
Gain on embedded derivative | ||||||||
- | - | - | - | - | - | - | - | 670 |
Other income (expense), net | ||||||||
- | - | - | - | - | - | - | - | 355 |
Interest income | ||||||||
- | - | - | - | 968 | 467 | 248 | 118 | 83 |
Interest expense | ||||||||
- | - | - | - | 8 | 18 | 31 | - | 3,161 |
Change in fair value of warrant liability and Series 1 nonconvertible preferred stock | ||||||||
- | -59 | -159 | 29 | 347 | -166 | 381 | -8 | -686 |
Total other income (expense), net | ||||||||
8,819 | 4,793 | 2,333 | 1,719 | 1,307 | 283 | 598 | 110 | -1,989 |
Income (loss) before income taxes | ||||||||
45,557 | 93,121 | 26,947 | 32,560 | 125,455 | 19,268 | 9,627 | 21,399 | - |
Income tax (expense) benefit | ||||||||
-826 | 21,165 | 9,237 | 10,894 | 46,463 | -15,170 | 0 | 0 | - |
Net income (loss) | ||||||||
46,383 | 71,956 | 17,710 | 21,666 | 78,992 | 34,438 | 9,627 | 21,399 | 23,310 |
Accretion of redeemable convertible preferred stock to redemption value | ||||||||
- | - | - | - | - | - | 2,526 | 5,367 | 5,454 |
Net income attributable to participating securities | ||||||||
- | - | - | - | - | - | 13,670 | 14,663 | 16,291 |
Net income (loss) attributable to common stockholders | ||||||||
- | - | - | - | - | - | -6,569 | 1,369 | 1,565 |
Net income (loss) per share: | ||||||||
Basic | ||||||||
2.37 | 3.74 | 0.93 | 1.14 | 4.23 | 1.88 | -0.67 | 1.26 | 1.40 |
Diluted | ||||||||
2.21 | 3.48 | 0.91 | 1.13 | 4.09 | 1.80 | -0.67 | 1.13 | 1.32 |
Weighted average shares outstanding: | ||||||||
Basic | ||||||||
19,584 | 19,255 | 19,066 | 18,929 | 18,673 | 18 | 9,788 | 1,088 | 1,119 |
Diluted | ||||||||
20,968 | 20,650 | 19,407 | 19,224 | 19,295 | 19 | 9,788 | 2,474 | 1,857 |
Royalties [Member] | ||||||||
Total revenue | ||||||||
205,197 | 191,625 | 37,814 | 57,692 | 34,077 | - | - | - | - |
Milestone [Member] | ||||||||
Total revenue | ||||||||
- | 15,000 | 65,000 | 30,000 | 125,000 | 40,000 | 26,000 | - | - |
Other [Member] | ||||||||
Total revenue | ||||||||
- | - | - | 576 | 1,803 | 7,741 | 6,053 | - | - |